Aclaris Therapeutics Inc (NASDAQ: ACRS)’s stock price has gone rise by 5.17 in comparison to its previous close of 1.16, however, the company has experienced a -0.81% decrease in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-05 that Here is how Aclaris Therapeutics (ACRS) and Aldeyra Therapeutics, Inc. (ALDX) have performed compared to their sector so far this year.
Is It Worth Investing in Aclaris Therapeutics Inc (NASDAQ: ACRS) Right Now?
The 36-month beta value for ACRS is also noteworthy at 0.24. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ACRS is 64.47M, and at present, short sellers hold a 7.59% of that float. The average trading volume of ACRS on April 12, 2024 was 1.47M shares.
ACRS’s Market Performance
ACRS stock saw a decrease of -0.81% in the past week, with a monthly decline of 0.00% and a quarterly a decrease of 21.39%. The volatility ratio for the week is 5.02%, and the volatility levels for the last 30 days are 6.66% for Aclaris Therapeutics Inc (ACRS). The simple moving average for the past 20 days is 1.92% for ACRS’s stock, with a -71.74% simple moving average for the past 200 days.
Analysts’ Opinion of ACRS
Evercore ISI gave a rating of “Outperform” to ACRS, setting the target price at $22 in the report published on October 03rd of the previous year.
ACRS Trading at 0.68% from the 50-Day Moving Average
After a stumble in the market that brought ACRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -89.03% of loss for the given period.
Volatility was left at 6.66%, however, over the last 30 days, the volatility rate increased by 5.02%, as shares sank -2.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.83% upper at present.
During the last 5 trading sessions, ACRS fell by -0.81%, which changed the moving average for the period of 200-days by -87.54% in comparison to the 20-day moving average, which settled at $1.1955. In addition, Aclaris Therapeutics Inc saw 16.19% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRS starting from Powell Andrew Kenneth William, who purchase 6,000 shares at the price of $1.25 back on Mar 04 ’24. After this action, Powell Andrew Kenneth William now owns 28,863 shares of Aclaris Therapeutics Inc, valued at $7,500 using the latest closing price.
Powell Andrew Kenneth William, the Director of Aclaris Therapeutics Inc, purchase 8,500 shares at $1.23 during a trade that took place back on Mar 01 ’24, which means that Powell Andrew Kenneth William is holding 22,863 shares at $10,455 based on the most recent closing price.
Stock Fundamentals for ACRS
Current profitability levels for the company are sitting at:
- -3.14 for the present operating margin
- 0.66 for the gross margin
The net margin for Aclaris Therapeutics Inc stands at -2.78. The total capital return value is set at -0.59. Equity return is now at value -49.88, with -38.68 for asset returns.
Based on Aclaris Therapeutics Inc (ACRS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -183.86. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 61.35.
Currently, EBITDA for the company is -134.41 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 1.51. The receivables turnover for the company is 104.86for trailing twelve months and the total asset turnover is 0.16. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.16.
Conclusion
In summary, Aclaris Therapeutics Inc (ACRS) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
